Belite Bio Inc
BLTE
Company Profile
Business description
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
Contact
12750 High Bluff Drive
Suite 475
San DiegoCA92130
USAT: +1 858 246-6240
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
25
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,830.00 | 9.70 | 0.11% |
| CAC 40 | 7,829.29 | 72.96 | -0.92% |
| DAX 40 | 24,255.31 | 201.50 | -0.82% |
| Dow JONES (US) | 44,371.51 | 279.13 | -0.63% |
| FTSE 100 | 8,941.12 | 34.54 | -0.38% |
| HKSE | 24,166.03 | 26.46 | 0.11% |
| NASDAQ | 20,585.53 | 45.14 | -0.22% |
| Nikkei 225 | 39,574.64 | 4.96 | 0.01% |
| NZX 50 Index | 12,659.93 | 26.75 | -0.21% |
| S&P 500 | 6,259.75 | 20.71 | -0.33% |
| S&P/ASX 200 | 8,586.90 | 6.80 | 0.08% |
| SSE Composite Index | 3,525.40 | 15.22 | 0.43% |